# A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

> **NCT06933472** · PHASE3 · RECRUITING · sponsor: **Alebund Pharmaceuticals** · enrollment: 264 (estimated)

## Conditions studied

- Hyperphosphatemia
- Chronic Kidney Disease, Receiving Dialysis
- ESRD (End-Stage Renal Disease)
- Dialysis

## Interventions

- **DRUG:** AP301
- **DRUG:** AP301 Low Dose

## Key facts

- **NCT ID:** NCT06933472
- **Lead sponsor:** Alebund Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-13
- **Primary completion:** 2026-06-20
- **Final completion:** 2027-01-10
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06933472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06933472, "A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06933472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*